SETDB2 Antibody Summary
| Immunogen |
Recombinant protein encompassing a sequence within the N-terminus region of human SETDB2. The exact sequence is proprietary.
|
| Localization |
Nucleus
|
| Isotype |
IgG
|
| Clonality |
Polyclonal
|
| Host |
Rabbit
|
| Gene |
SETDB2
|
| Purity |
Immunogen affinity purified
|
| Innovators Reward |
Test in a species/application not listed above to receive a full credit towards a future purchase.
Learn about the Innovators Reward
|
Applications/Dilutions
| Dilutions |
|
| Application Notes |
The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
|
| Theoretical MW |
82 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors. |
Packaging, Storage & Formulations
| Storage |
Aliquot and store at -20C or -80C. Avoid freeze-thaw cycles.
|
| Buffer |
PBS (pH 7.0) and 20% Glycerol
|
| Preservative |
0.01% Thimerosal
|
| Concentration |
1 mg/ml
|
| Purity |
Immunogen affinity purified
|
Alternate Names for SETDB2 Antibody
- C13orf4
- chromosome 13 open reading frame 4
- chronic lymphocytic leukemia deletion region 8
- Chronic lymphocytic leukemia deletion region gene 8 protein
- CLLD8DKFZp761J1217
- DKFZp586I0123
- EC 2.1.1.43
- histone-lysine N-methyltransferase SETDB2
- KMT1FCLLL8
- Lysine N-methyltransferase 1F
- SET domain bifurcated 2
- SET domain, bifurcated 2
Background
Proteins that contain a SET domain, such as SETDB2, modulate gene expression epigenetically through histone H3 (see MIM 601128) methylation. SETDB2 is likely a histone H3 methyltransferase, as it contains both the active site and flanking cysteine residues required for catalytic activity (Zhang et al., 2003 [PubMed 12754510]).[supplied by OMIM]